I posted this yesterday but it seemed to have disappeared and hour later.
DNA executives at BIIB is not a new thing. They may be considering using Oceanside to produce more Rituxan for its ever increasing uses. BGEN had been working with DNA before it became BIIB on another class of immunosuppressives that may be getting closer to cllinical trials and need to produce drug for that--BIIB would benifit as does DNA. Maybe they were looking the place over but it doesn't mean a buy out--but then again it could.
Without T BIIB is a much better investment. With T, Elan runs up more %-wise and if the AD program succeeds will blow BIIB's numbers away. Lots of "ifs" though. So, BIIB safer, Elan more risk, more potential reward. Your call.